Ionis Pharmaceuticals Inc (NASDAQ: IONS) on Tuesday, plunged -0.92% from the previous trading day, before settling in for the closing price of $43.45. Within the past 52 weeks, IONS’s price has moved between $23.95 and $50.43.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 10.16%. With a float of $155.51 million, this company’s outstanding shares have now reached $159.20 million.
Considering the fact that the conglomerate employs 1069 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 98.9%, operating margin of -28.21%, and the pretax margin is -29.02%.
Ionis Pharmaceuticals Inc (IONS) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Ionis Pharmaceuticals Inc is 2.44%, while institutional ownership is 104.04%. The most recent insider transaction that took place on Aug 04 ’25, was worth 408,701. In this transaction EVP, Chf Clinical Develop Ofcr of this company sold 9,549 shares at a rate of $42.80, taking the stock ownership to the 51,507 shares. Before that another transaction happened on Aug 05 ’25, when Company’s Officer proposed sale 10,000 for $42.86, making the entire transaction worth $428,593.
Ionis Pharmaceuticals Inc (IONS) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 10.16% per share during the next fiscal year.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Trading Performance Indicators
Ionis Pharmaceuticals Inc (IONS) is currently performing well based on its current performance indicators. A quick ratio of 2.86 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.85, a number that is poised to hit -1.20 in the next quarter and is forecasted to reach -3.13 in one year’s time.
Technical Analysis of Ionis Pharmaceuticals Inc (IONS)
Compared to the last year’s volume of 1.75 million, its volume of 3.04 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 48.80%.
During the past 100 days, Ionis Pharmaceuticals Inc’s (IONS) raw stochastic average was set at 87.98%, which indicates a significant increase from 46.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.32 in the past 14 days, which was higher than the 1.31 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $39.20, while its 200-day Moving Average is $35.11.
